Sol-Gel Technologies Ltd. Stock: price and insider trades · United States
1 insider bought €3.3M of shares over the last 90 days, the latest by Opaleye Management Inc., filed 14 Sept 2026.
Sol-Gel Technologies Ltd.: what insiders have been doing
Sol-Gel Technologies Ltd. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). 1 insider has disclosed 44 filings since 22 October 2025.
Only purchases show up on the open market, 44 purchases in all worth €9.3M, filed by 1 insider. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. At €2.2M, the purchase published on 24 March 2026 by Opaleye Management Inc. is the largest of the period. Among those who bought: 1 major shareholder.
Across the 3,171 companies tracked on its exchange, the median is 24 filings; at 44 filings, this issuer sits above that mark. Since 2025, the database holds 44 purchases and no sales by insiders of the company. In its latest annual report filed with the SEC (20-F, fiscal year ended 31 December 2025), the company reported revenue of 19.4 m USD and net income of -6.1 m USD.
The most recent open-market purchase was published on 14 September 2026, 55 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4.
For comparison within the same sector, see the insider buying recorded at UCB. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleSince the insiders bought
- +0.9%Entry US$64.40 · Close 19 Oct 2026 US$64.98
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Sol-Gel Technologies Ltd. Strong Buy (bullish), based on 2 analysts. Average price target: US$152.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 1,631 shares@ US$66.7950.050% mcap1.4% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-042615:0Canonical exit: 9 Dec 2026 (T+90)
- 1,493 shares@ US$65.9450.045% mcap1.3% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-042615:1Canonical exit: 10 Dec 2026 (T+90)
- 918 shares@ US$69.520.029% mcap0.6% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-042023:0Canonical exit: 3 Dec 2026 (T+90)
- 2,100 shares@ US$68.980.065% mcap1.3% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-042023:1Canonical exit: 3 Dec 2026 (T+90)
- 3,390 shares@ US$68.74030.10% mcap2.1% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-042023:2Canonical exit: 7 Dec 2026 (T+90)
- 471 shares@ US$69.370.015% mcap0.3% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-042023:3Canonical exit: 7 Dec 2026 (T+90)
- 3,097 shares@ US$68.7050.095% mcap2.0% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-042023:4Canonical exit: 8 Dec 2026 (T+90)
- 783 shares@ US$69.520.024% mcap0.7% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-041363:0Canonical exit: 30 Nov 2026 (T+90)
- 900 shares@ US$68.94890.028% mcap0.8% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-041363:1Canonical exit: 1 Dec 2026 (T+90)
- 10,000 shares@ US$71.39690.32% mcap9.1% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-040895:0Canonical exit: 26 Nov 2026 (T+90)
- 20,113 shares@ US$68.42030.61% mcap17.6% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-040895:1Canonical exit: 26 Nov 2026 (T+90)
- 5,000 shares@ US$68.810.15% mcap4.4% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-040895:2Canonical exit: 26 Nov 2026 (T+90)
- 5,000 shares@ US$68.2350.15% mcap4.4% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-040895:3Canonical exit: 29 Nov 2026 (T+90)
- 217 shares@ US$69.100.0067% mcap0.2% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-040895:4Canonical exit: 29 Nov 2026 (T+90)
- 951 shares@ US$71.500.031% mcap0.9% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-038304:0Canonical exit: 10 Nov 2026 (T+90)
- 775 shares@ US$73.88730.026% mcap0.8% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-033354:0Canonical exit: 11 Oct 2026 (T+90)
- 920 shares@ US$73.43040.031% mcap0.9% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-033354:1Canonical exit: 12 Oct 2026 (T+90)
- 229 shares@ US$73.950.0077% mcap0.2% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-032859:1Canonical exit: 8 Oct 2026 (T+90)
- 300 shares@ US$73.690.010% mcap0.3% of flowOrdinary Shares, par value NIS 1.00 per shareSEC:0001493152-26-032859:0Canonical exit: 6 Oct 2026 (T+90)
- 1,500 shares@ US$67.98330.037% mcap1.3% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-26-023056:0Canonical exit: 10 Aug 2026 (T+90)
- 5,000 shares@ US$72.003.3% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-26-012354:1Canonical exit: 22 Jun 2026 (T+90)
- 34,665 shares@ US$72.0032.1% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-26-012354:0Canonical exit: 22 Jun 2026 (T+90)
- 291 shares@ US$63.000.2% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-26-007330:0Canonical exit: 14 May 2026 (T+90)
- 100 shares@ US$58.000.1% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-26-005094:0Canonical exit: 3 May 2026 (T+90)
- 100 shares@ US$57.050.1% of flowOrdinary Shares, par value NIS 1.00 per share.SEC:0001493152-26-004234:0Canonical exit: 27 Apr 2026 (T+90)
25 of 44 declarations
About Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd. is a U.S.-listed specialty biopharmaceutical company traded on the NASDAQ in the United States (United States), with a focused footprint in dermatology. The company was founded on October 28, 1997, and is headquartered in Ness Ziona, Israel, at Weizmann Science Park. Its core strategy is centered on developing and commercializing topical therapies for severe, rare, and high-unmet-need skin diseases, supported by a proprietary microencapsulation-based formulation platform designed to improve local delivery and tolerability of dermatologic actives. ([ir.sol-gel.com](https://ir.sol-gel.com/resources/investor-faqs?utm_source=openai))
Sol-Gel’s commercial history is anchored by two FDA-approved products: TWYNEO®, for acne vulgaris in adults and pediatric patients nine years of age and older, and EPSOLAY®, for inflammatory lesions of rosacea in adults. These approvals demonstrate the company’s ability to progress dermatology assets through clinical development and regulatory review. More recently, Sol-Gel has shifted increasing attention toward its proprietary pipeline, led by SGT-610, a topical patidegib gel currently in Phase 3 development for the prevention of new basal cell carcinoma lesions in patients with Gorlin syndrome. The pipeline also includes SGT-210, a topical erlotinib candidate being studied in Darier disease and other rare keratinization disorders. ([ir.sol-gel.com](https://ir.sol-gel.com/node/8896?utm_source=openai))
Read moreShow less
From a competitive standpoint, Sol-Gel remains a niche player relative to large global dermatology and specialty-pharma groups, but it has carved out a differentiated profile through focused topical formulation expertise, demonstrated regulatory execution, and a partnership-driven commercialization model outside the United States. The company has signed multiple ex-U.S. licensing agreements for TWYNEO and EPSOLAY, including arrangements in Europe, South Africa, Australia, and New Zealand, which broaden geographic reach while reducing the need for a large internal sales infrastructure. ([ir.sol-gel.com](https://ir.sol-gel.com/news-releases/news-release-details/sol-gel-announces-signing-six-exclusive-license-agreements?utm_source=openai))
A key recent development was the April 2025 sale of the U.S. rights to EPSOLAY and TWYNEO to Mayne Pharma, following the mutual termination of Sol-Gel’s exclusive U.S. license agreement with Galderma. That transaction materially reshaped the company’s U.S. commercial exposure and made the clinical pipeline, especially SGT-610, even more central to the investment case. In March 2026, Sol-Gel also completed a new underwritten offering, underscoring that liquidity management and capital access remain important priorities as the company continues to fund clinical development and prepare for potential future commercialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1684693/000117891325002946/exhibit_99-1.htm?utm_source=openai))
